Sci Transl Med：环糊精有望治疗动脉粥样硬化

2016-04-15 新华社郭洋《科学转化医学》

德国等国研究人员6日在美国《科学转化医学》杂志上报告说，环状低聚糖——环糊精可起到阻止甚至减少胆固醇结晶沉积的作用，有望用于治疗动脉粥样硬化。动脉粥样硬化是指动脉壁上沉积一层包括胆固醇结晶在内的粥样物质，使动脉弹性降低、管腔变窄，常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应，导致动脉壁出现可致命的炎症。先前研究发现，环糊精可缓解先天性糖脂代谢性疾病——C型尼曼匹克氏症患者脑

德国等国研究人员6日在美国《科学转化医学》杂志上报告说，环状低聚糖——环糊精可起到阻止甚至减少胆固醇结晶沉积的作用，有望用于治疗动脉粥样硬化。

动脉粥样硬化是指动脉壁上沉积一层包括胆固醇结晶在内的粥样物质，使动脉弹性降低、管腔变窄，常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应，导致动脉壁出现可致命的炎症。

先前研究发现，环糊精可缓解先天性糖脂代谢性疾病——C型尼曼匹克氏症患者脑细胞内的胆固醇运输障碍。德国波恩大学等机构的研究人员据此猜测，环糊精可能有助于清除动脉粥样硬化患者动脉壁上沉积的胆固醇结晶

研究人员持续8周给实验鼠喂食高胆固醇食物，并给一部分实验鼠注射了环糊精。结果显示，实验鼠在注射环糊精后，血管中的沉积物要比其他实验鼠少很多。环糊精提高了细胞清除胆固醇的能力，并减少了血管中的炎症反应。研究人员利用人类动脉粥样硬化患者血管中的沉积物展开的研究也得出上述结论。

研究人员表示，环糊精可用于研发动脉粥样硬化治疗药物。不过，虽然环糊精作为一些难溶性药物的增溶剂早已进入市场，但将其作为治疗动脉粥样硬化的新药还需进一步临床研究。

原始出处：

Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, Skjelland M, De Nardo D, Labzin LI, Kerksiek A, Hempel C, Heneka MT, Hawxhurst V, Fitzgerald ML, Trebicka J, Björkhem I, Gustafsson JÅ, Westerterp M, Tall AR, Wright SD, Espevik T, Schultze JL, Nickenig G, Lütjohann D, Latz E. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med. 2016 Apr 6;8(333):333ra50

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (9)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2017-03-10 bsmagic9140

#TRA#

60 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2017-01-12 ms3025846204744509

#Transl#

71 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-08-06 huangshifeng

#粥样硬化#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-17 ms3994565386320060

#Med#

64 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-16 1de7460am01(暂无匿称)

这就是创新

126 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-16 1de3b290m83(暂无匿称)

中医药

141 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-16 Wechat4343a314

记住环瑚精

176 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-16 李继凯

高大上的文章

144 0
[GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
2016-04-16 李继凯

值得关注

151 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

转化医学

Sci Transl Med：环糊精有望治疗动脉粥样硬化

相关资讯

科室

工具

服务